SSE STAR Market
Every company in the roster listed on SSE STAR Market.
Every company in the roster listed on SSE STAR Market.
13 of 13 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Allist Pharmaceuticals688578 · SSE STAR Market | 4 assets: 3 Ph 3, 1 Ph 1 | GlecirasibPhase 3 · Non-Small Cell Lung CancerWeak signal | Dec 2026AST2303 · Phase 1 | — | — | — | $75M |
Asieris Pharmaceuticals688176 · SSE STAR Market | 1 asset: 1 Ph 1 | NepicastatPhase 1 · Ulcerative ColitisWeak signal | None on record | — | $91MMar 2026 | ~5.6 qtrs | $49M |
BeBetter Med688759 · SSE STAR Market | 4 assets: 2 Ph 3, 2 Ph 2 | IfupinostatPhase 3 · Relapsed/Refractory Diffuse Large B-Cell LymphomaWeak signal | Jun 2027BEBT-109 · Phase 2 | — | $144MDec 2025 | ~6.7 qtrs | $17M |
Bio-Thera Solutions688177 · SSE STAR Market | 7 assets: 3 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1 | BAT3306Phase 3 · Non-Small Cell Lung CancerPartial signal | 31 Dec 2026Vedastotug · Phase 1/2 | — | — | — | — |
Dizal Pharmaceuticals688192 · SSE STAR Market | 2 assets: 1 approved, 1 Ph 2 | DZD6008Phase 1/2 · Non-Small Cell Lung Cancer | Jun 2027DZD6008 · Phase 1/2 | — | $42MDec 2025 | Ended Feb 2026 | $119M |
Frontier Biotechnologies688221 · SSE STAR Market | 2 assets: 1 Ph 3, 1 Ph 2 | AlbuvirtidePhase 3 · HIVPartial signal | None on record | — | — | — | $20M |
Genrix Bio688443 · SSE STAR Market | 3 assets: 2 Ph 3, 1 Ph 1 | Velinotamig (GR1803)Phase 3 · Multiple MyelomaWeak signal | 12 May 2027Velinotamig (GR1803) · Phase 2 | — | — | — | $66M |
InventisBio688382 · SSE STAR Market | 4 assets: 4 Ph 3 | BefotertinibPhase 3 · Non-Small Cell Lung CancerPartial signal | 21 Nov 2026Nomelcitinib (D-2570) · Phase 1 | — | $173MJun 2026 | ~17.3 qtrs | ~$54M |
Mabwell Bioscience688062 · SSE STAR Market | 3 assets: 2 Ph 3, 1 Ph 2 | 7MW3711Phase 3 · Non-Small Cell Lung Cancer | Dec 20279MW1911 · Phase 2 | — | — | — | ~$95M |
Sichuan Baili Pharmaceutical688506 · SSE STAR Market | 9 assets: 3 Ph 3, 4 Ph 2, 2 Ph 1 | IzalontamabPhase 3 · Non-Small Cell Lung Cancer | Nov 2026Izalontamab brengitecan · Phase 3 | — | $430MMar 2026 | — | $350M |
Sichuan Huiyu Pharmaceutical Co., Ltd688553 · SSE STAR Market | 1 asset: 1 Ph 2 | HYP-6589Phase 1/2 · Non-Small Cell Lung Cancer | 10 Apr 2028HYP-6589 · Phase 1/2 | — | — | — | — |
Sunshine Guojian Pharmaceutical688336 · SSE STAR Market | 3 assets: 2 Ph 3, 1 Ph 2 | Amdokitug (Yisaituo)Phase 3 · Psoriasis | 14 Jan 2027Amdokitug (Yisaituo) · Phase 3 | — | $243MDec 2025 | Profitable | — |
Suzhou Zelgen Biopharmaceuticals688266 · SSE STAR Market | 2 assets: 2 Ph 3 | jaktinibPhase 3 · Atopic DermatitisPartial signal | Feb 2027jaktinib · Phase 1 | — | $18MDec 2025 | — | $60M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.